Cholesterol

As part of the 2020 Year in Review, Cardiology Today compiled a list of selected drugs and devices related to the specialty that were newly approved or cleared or were granted a new indication. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omissions. Appearance of a drug or device does not constitute any endorsement by Cardiology Today, its editors, publisher or editorial board. – The Editors

Women from China who had early menarche were more likely to develop type 2 diabetes as adults, with the risk higher for those with nonideal cardiovascular health, according to data from the REACTION study.

In a new study, levels of triglycerides and remnant cholesterol — but not LDL or HDL — were associated with major CVD outcomes, independent of lifestyle and other risk factors, in older adults with high CV risk and overweight or obesity.

Adults at intermediate CV risk assigned a polypill plus aspirin were 31% less likely to experience a CV event or death compared with those assigned double placebo over a nearly 5-year period, according to new data from the TIPS-3 trial.

Green tea and coffee consumption may reduce the risk for mortality among adults with type 2 diabetes, according to a recent study. It was the top story in endocrinology last week. 

Within couples, there was often similar adherence or nonadherence to ideal CV health behaviors, which may represent an opportunity for targeted risk factor modification, researchers reported.

All adults with endocrine disorders should undergo measurement of cholesterol and triglyceride levels to better manage their cardiovascular risk, according to a new clinical practice guideline from the Endocrine Society.

In the United States, primary care visits declined 21.4% during the second quarter of 2020 compared with average visit volumes in 2018 and 2019, according to study results recently published in JAMA Network Open.

The term “metabolic syndrome” has been used since the mid-1990s to describe a constellation of risk factors that predispose adults to develop diabetes, CVD or both.

The American Heart Association released a scientific statement that claims there is no documented benefit of cannabis use for CVD prevention or treatment. It was the top story in cardiology last week.